This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-23. Anything still debated is marked as such rather than presented as settled.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
In 1987 the United States Environmental Protection Agency (EPA) classified it as a probable human carcinogen, and after more studies the WHO International Agency for Research on Cancer (IARC) in 1995 also classified it as a probable human carcinogen. Further information and evaluation of all known data led the IARC to reclassify formaldehyde as a known human carcinogen associated with nasal sinus cancer and nasopharyngeal cancer. Studies in 2009 and 2010 have also shown a positive correlation between exposure to formaldehyde and the development of leukemia, particularly myeloid leukemia. Nasopharyngeal and sinonasal cancers are relatively rare, with a combined annual incidence in the United States of less than 4,000 cases. About 30,000 cases of myeloid leukemia occur in the United States each year. Some evidence suggests that workplace exposure to formaldehyde contributes to sinonasal cancers. Professionals exposed to formaldehyde in their occupation, such as funeral industry workers and embalmers, showed an increased risk of leukemia and brain cancer compared with the general population. Other factors are important in determining individual risk for the development of leukemia or nasopharyngeal cancer. In yeast, formaldehyde is found to perturb pathways for DNA repair and cell cycle. In the residential environment, formaldehyde exposure comes from a number of routes: formaldehyde can be emitted by treated wood products, such as plywood or particle board, but it is also produced by paints, varnishes, floor finishes, and cigarette smoking.
The Bristol stool scale is a diagnostic medical tool designed to classify the form of human faeces into seven categories. It is used in both clinical and experimental fields. It was developed at the Bristol Royal Infirmary as a clinical assessment tool in 1997, by Stephen Lewis and Ken Heaton and is widely used as a research tool to evaluate the effectiveness of treatments for various diseases of the bowel, as well as a clinical communication aid; including being part of the diagnostic triad for irritable bowel syndrome.
=== NNPC Bags Transparency Award === The efforts of the Mallam Mele Kyari-led Management of the Nigerian National Petroleum Corporation (NNPC) to entrench the culture of transparency in the system have begun to receive recognition with the Corporation named as the “Government Agency of the Year 2020 (Transparency)” by the New Telegraph.
Sources: en.wikipedia.org
The disappointment was mitigated when the composition of the Government was known, in which the most prominent figures of Franco's "reformism" appeared, such as Manuel Fraga Iribarne, José María de Areilza and Antonio Garrigues y Díaz Cañabate. Other Francoist "reformists" from the Catholic (Alfonso Osorio) and Falangist "families" (the "blue reformists", Adolfo Suárez and Rodolfo Martin Villa) also participated in this government. Actually, the members of the government were imposed on Arias Navarro by the king, and in the case of Suárez it had been a suggestion of Fernández Miranda. This new government was often referred to in the press as the "Arias-Fraga-Areilza-Garrigues government".
== Current application of LED light therapy == Red light therapy, utilising red LED lights, originated from techniques intended to enhance plant growth in space and aid in astronauts' wound healing. Primarily used in dermatology, it enhances skin conditions by stimulating mitochondria, thereby increasing collagen production and blood circulation while reducing inflammation. Additionally, it plays a crucial role in photodynamic therapy, where it combines with photosensitive drugs to target and destroy cancerous cells through a light-induced chemical reaction. Blue light therapy is also a common LED light therapy to treat acne, skin cancer, and depression. While blue light therapy has similar mechanisms for skin enhancement as red light therapy, its usage for photodynamic therapies in treating cancer are slightly different. Blue light therapy stimulates immune system defences, destroys blood vessels that help cancer cells grow, and causes cell death by reacting with oxygen. It also prevents skin cancer and metastasis by removing precancerous and cancerous skin lesions. Application of red and blue LED light for photodynamic treatments are generally safe and can be used to treat different cancers. However, they may differ in the efficiency and response. For instance, In the treatment of Gorlin syndrome, a genetic disorder predisposed to cancer, studies have shown that blue light therapy achieves a higher tumor clearance rate and induces less pain than red light therapy.
=== Reported end of outbreak: August–September 2022 === On 5 August 2022, the country reported that it had not seen a fever case for seven consecutive days, and that every fever case had recovered. On 8 August, plans were announced to convene the Supreme People's Assembly in September, moving its members out of isolation. A separate review meeting to discuss a "change in direction" in pandemic response was also announced. On 11 August, Kim Jong Un's sister, Kim Yo Jong, stated that her brother had had a fever, implying that he had COVID-19 at one point. She also blamed South Korea for the COVID-19 outbreak in the country, claiming that it sent contaminated anti-Pyongyang leaflets to spread the disease. North Korean media reports indicate that the population have resumed regular activity. On August 25, several sources told NK News that North Korea could possibly allow foreigners into North Korea for the first time since 2020, likely after the 20th National Congress of the Chinese Communist Party later in 2022. In September, however, Kim Jong Un flagged the first rollout of vaccines in November and warned that COVID-19 could reappear in the winter months. The mass vaccination program started in the border areas in late September, making North Korea the last country in the world other than Eritrea to have a mass vaccination program against COVID-19.
Sources: en.wikipedia.org
There are a number of mechanisms through which religion may make a person happier, including social contact and support that result from religious pursuits, the mental activity that comes with optimism and volunteering, learned coping strategies that enhance one's ability to deal with stress, and psychological factors such as "reason for being." It may also be that religious people engage in behaviors related to good health, such as less substance abuse, since the use of psychotropic substances is sometimes considered abuse. The Handbook of Religion and Health describes a survey by Feigelman (1992) that examined happiness in Americans who have given up religion, in which it was found that there was little relationship between religious disaffiliation and unhappiness. A survey by Kosmin & Lachman (1993), also cited in this handbook, indicates that people with no religious affiliation appear to be at greater risk for depressive symptoms than those affiliated with a religion. A review of studies by 147 independent investigators found, "the correlation between religiousness and depressive symptoms was -.096, indicating that greater religiousness is mildly associated with fewer symptoms." The Legatum Prosperity Index reflects the repeated finding of research on the science of happiness that there is a positive link between religious engagement and well-being: people who report that God is very important in their lives are on average more satisfied with their lives, after accounting for their income, age and other individual characteristics.
== Examples of variants == Over 1,000 known mutations can lead to thalassaemia or hemoglobin variants. A research database of hemoglobin variants is maintained by Penn State University. A few of these variants are listed below.
=== Antioxidant capacity of chocolate and hops === The phenolic antioxidants for cocoa powder, dark chocolate, and milk chocolate can also be determined via cyclic voltammetry. In order to achieve this, the anodic peaks are calculated and analyzed with the knowledge that the first and third anodic peaks can be assigned to the first and second oxidation of flavonoids, while the second anodic peak represents phenolic acids. Using the graph produced by cyclic voltammetry, the total phenolic and flavonoid content can be deduced in each of the three samples. It was observed that cocoa powder and dark chocolate had the highest antioxidant capacity since they had high total phenolic and flavonoid content. Milk chocolate had the lowest capacity as it had the lowest phenolic and flavonoid content. While the antioxidant content was given using the cyclic voltammetry anodic peaks, HPLC must then be used to determine the purity of catechins and procyanidin in cocoa powder, dark chocolate, and milk chocolate. Hops, the flowers used in making beer, contain antioxidant properties due to the presence of flavonoids and other polyphenolic compounds. In this cyclic voltammetry experiment, the working electrode voltage was determined using a ferricinium/ferrocene reference electrode. By comparing different hop extract samples, it was observed that the sample containing polyphenols that were oxidized at less positive potentials proved to have better antioxidant capacity.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.